Literature DB >> 29334670

Genetic ablation of TRPV1 exacerbates pressure overload-induced cardiac hypertrophy.

Beihua Zhong1, Jack Rubinstein2, Shuangtao Ma1, Donna H Wang3.   

Abstract

Transient receptor potential vanilloid 1 (TRPV1) channels expressed in sensory nerves may regulate vascular tone and cardiovascular function via their anti-inflammatory effects by releasing neuropeptide calcitonin gene-related peptide (CGRP). Inflammation plays a role in the progression of cardiac hypertrophy and TRPV1 activation may be key to cardiac inflammatory processes. The aim of this study was to test the hypothesis that TRPV1 modulates inflammatory processes to protect the heart from pressure overload-induced hypertrophy and inflammatory responses. Trpv1 knockout (Trpv1-/-) and wild-type (WT) mice were subjected to transverse aortic constriction (TAC) or sham operation. Four weeks after TAC, WT and Trpv1-/- mice had developed left ventricular (LV) hypertrophy with increased LV mass, fibrosis and infiltration of macrophages as well as increased secretion of tumor necrosis factor α, interleukin-6 from cardiac tissue (all P < 0.05), those were higher in Trpv1-/- than in WT mice with TAC (all P < 0.05). In addition, decreases of LV ejection fraction and fractional shortening were greater in Trpv1-/- than in WT mice (both P < 0.05). Moreover, atrial natriuretic peptide level was greater in Trpv1-/- than in WT mice with TAC (P < 0.05). Compared to sham control, TAC procedure significantly increased cardiac TRPV1 expression and CGRP release in WT mice (both P < 0.05), but not in Trpv1-/- mice. These results demonstrate that Trpv1 gene deletion results in excessive inflammation, exaggerates cardiac hypertrophy, and deteriorates cardiac function after TAC, which may be due to abnormal cardiac remodeling and decreased CGRP in the absence of TRPV1.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Heart; Hypertrophy; Inflammation; Macrophage; TRPV1

Mesh:

Substances:

Year:  2018        PMID: 29334670     DOI: 10.1016/j.biopha.2018.01.065

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  10 in total

1.  Cardiac TRPV1 afferent signaling promotes arrhythmogenic ventricular remodeling after myocardial infarction.

Authors:  Koji Yoshie; Pradeep S Rajendran; Louis Massoud; Janki Mistry; M Amer Swid; Xiaohui Wu; Tamer Sallam; Rui Zhang; Joshua I Goldhaber; Siamak Salavatian; Olujimi A Ajijola
Journal:  JCI Insight       Date:  2020-02-13

2.  TRPV1 in experimental autoimmune prostatitis.

Authors:  Kenny Roman; Christel Hall; Anthony J Schaeffer; Praveen Thumbikat
Journal:  Prostate       Date:  2019-10-01       Impact factor: 4.104

3.  Inhibition of transient receptor potential vanilloid 1 (TRPV1) channel regulates chikungunya virus infection in macrophages.

Authors:  P Sanjai Kumar; Tapas K Nayak; Chandan Mahish; Subhransu S Sahoo; Anukrishna Radhakrishnan; Saikat De; Ankita Datey; Ram P Sahu; Chandan Goswami; Soma Chattopadhyay; Subhasis Chattopadhyay
Journal:  Arch Virol       Date:  2020-10-30       Impact factor: 2.574

Review 4.  Channelling the Force to Reprogram the Matrix: Mechanosensitive Ion Channels in Cardiac Fibroblasts.

Authors:  Leander Stewart; Neil A Turner
Journal:  Cells       Date:  2021-04-23       Impact factor: 6.600

Review 5.  Capsaicin-Sensitive Sensory Nerves and the TRPV1 Ion Channel in Cardiac Physiology and Pathologies.

Authors:  Tamara Szabados; Kamilla Gömöri; Laura Pálvölgyi; Anikó Görbe; István Baczkó; Zsuzsanna Helyes; Gábor Jancsó; Péter Ferdinandy; Péter Bencsik
Journal:  Int J Mol Sci       Date:  2020-06-23       Impact factor: 5.923

Review 6.  Alpha-Calcitonin Gene Related Peptide: New Therapeutic Strategies for the Treatment and Prevention of Cardiovascular Disease and Migraine.

Authors:  Ambrish Kumar; Maelee Williamson; Andrew Hess; Donald J DiPette; Jay D Potts
Journal:  Front Physiol       Date:  2022-02-11       Impact factor: 4.566

7.  Transient Receptor Potential Vanilloid Type 1 Protects Against Pressure Overload-Induced Cardiac Hypertrophy by Promoting Mitochondria-Associated Endoplasmic Reticulum Membranes.

Authors:  Yuxiang Wang; Xiuchuan Li; Xiaoli Xu; Xuemei Qu; Yongjian Yang
Journal:  J Cardiovasc Pharmacol       Date:  2022-09-01       Impact factor: 3.271

Review 8.  Transient receptor potential vanilloid subtype 1: A potential therapeutic target for fibrotic diseases.

Authors:  Guangxin Peng; Xiaoling Tang; Yang Gui; Jing Yang; Lifang Ye; Liuyang Wu; Ya Hui Ding; Lihong Wang
Journal:  Front Physiol       Date:  2022-08-15       Impact factor: 4.755

Review 9.  Does Transient Receptor Potential Vanilloid Type 1 Alleviate or Aggravate Pathological Myocardial Hypertrophy?

Authors:  Qiqi Yan; Jun Tang; Xin Zhang; Liuyang Wu; Yunyi Xu; Lihong Wang
Journal:  Front Pharmacol       Date:  2021-05-10       Impact factor: 5.810

10.  TRPV1 activation and internalization is part of the LPS-induced inflammation in human iPSC-derived cardiomyocytes.

Authors:  Katherine Sattler; Ibrahim El-Battrawy; Lukas Cyganek; Siegfried Lang; Huan Lan; Xin Li; Zhihan Zhao; Jochen Utikal; Thomas Wieland; Martin Borggrefe; Xiaobo Zhou; Ibrahim Akin
Journal:  Sci Rep       Date:  2021-07-19       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.